CD147 and glioma: a meta-analysis

TLDR: CD147 expression may be a potential prognostic biomarker for poorer overall and relapse-free survival, and may affect the 5-year survival rate in glioma patients.

Abstract: Gliomas are the most common primary brain tumors This meta-analysis aimed to systematically evaluate the relationship between CD147 expression in tissues and the clinicopathological features of patients with glioma We searched PubMed (1966–2016), EMBASE (1980–2016), Cochrane Library (1996–2016), Web of Science (1945–2016), China National Knowledge Infrastructure (1982–2016), and Wan Fang databases (1988–2016) Quality assessment of the literature was performed using the Newcastle–Ottawa Scale, with Revman 53 and Stata 140 for analysis In total, 1806 glioma patients from 19 studies were included, and patients with CD147 overexpression had poorer overall survival [hazard ratio (HR) = 2211, P < 00001], a higher risk of recurrence (HR = 220, P = 00025), and a lower 5-year survival rate [odds ratio (OR) 012; 95% CI 008–019; P < 000001] We observed significant differences in CD147 expression when comparing glioma tissues versus non-cancerous brain tissues (OR 2042; 95% CI 1394–2991; P < 000001), tumor grades III–IV versus grades I–II (OR 588, 95% CI 415–834; P < 000001), and large versus small tumors (OR 158, 95% CI 104–240; P = 003) We also observed a significant correlation with matrix metalloproteinase (MMP) 2 (OR 3911, 95% CI 1147–13334; P < 000001) and MMP9 (OR 1335, 95% CI 467–3818; P < 000001) CD147 expression did not differ based on patient’s age (young vs old, P = 089) or gender (female vs male, P = 057) CD147 expression may be a potential prognostic biomarker for poorer overall and relapse-free survival, and may affect the 5-year survival rate in glioma patients CD147 expression is also closely correlated with poor clinical characteristics in glioma patients